Comparative Effectiveness of Tocilizumab as Monotherapy Versus TNF inhibitors in Combination with Conventional Synthetic Disease Modifying Antirheu-matic Drugs in Bio-naive Patients with Rheumatoid Arthritis

被引：0
|
作者：
Lauper, K. [1 ,2 ]
Kvien, T. K. [3 ]
Codreanu, C. [4 ]
Hernandez, M., V [5 ]
Iannone, I. [6 ]
Kristianslund, E. K. [3 ]
Lukina, G. [7 ]
Nordstrom, D. C. [8 ,9 ]
Pavelka, K. [10 ]
Rotar, Z. [11 ]
Santos, M. J. [12 ,13 ]
Gale, S. L. [14 ]
John, M. [15 ]
Luder, Y. [15 ]
Courvoisier, D. S. [1 ]
Gabay, C. [1 ,2 ]
机构：
[1] Geneva Univ Hosp, Geneva, Switzerland
[2] SCQM Registry, Zurich, Switzerland
[3] Diakonhjemmet Hosp, Dept Rheumatol, Oslo, Norway
[4] Univ Med & Pharm, Ctr Rheumat Dis, Bucharest, Romania
[5] Hosp Clin Barcelona, Rheumatol Dept, Barcelona, Spain
[6] Univ Hosp Bari, GISEA, Bari, Italy
[7] Inst Rheumatol, ARBITER, Moscow, Russia
[8] ROB FIN Helsinki Univ Hosp, Helsinki, Finland
[9] Univ Helsinki, Helsinki, Finland
[10] Charles Univ Prague, Prague, Czech Republic
[11] Univ Med Ctr Ljubljana, BioRx Si, Ljubljana, Slovenia
[12] Hosp Garcia de Orta, Rheumatol Dept, Almada, Portugal
[13] Reuma Pt, Lisbon, Portugal
[14] Genentech Inc, San Francisco, CA USA
[15] F Hoffmann La Roche, Basel, Switzerland
来源：
SWISS MEDICAL WEEKLY | 2018年 / 148卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SSRP 35
引用
收藏
页码：20S / 20S
页数：1
相关论文
共 50 条
  • [21] A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population
    Kivitz, Alan J.
    Cohen, Stanley
    Keystone, Edward
    van Vollenhoven, Ronald F.
    Haraoui, Boulos
    Kaine, Jeffrey
    Fan, Haiyun
    Connell, Carol A.
    Bananis, Eustratios
    Takiya, Liza
    Fleischmann, Roy
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2018, 48 (03) : 406 - 415
  • [22] Discontinuation of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Excellent Disease Control
    Lillegraven, Siri
    Sundlisaeter, Nina Paulshus
    Aga, Anna-Birgitte
    Sexton, Joseph
    Solomon, Daniel H.
    van der Heijde, Desiree
    Haavardsholm, Espen A.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 329 (12): : 1024 - 1026
  • [23] Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study
    Gabay, Cem
    Riek, Myriam
    Hetland, Merete Lund
    Hauge, Ellen-Margrethe
    Pavelka, Karel
    Tomsic, Matija
    Canhao, Helena
    Chatzidionysiou, Katerina
    Lukina, Galina
    Nordstrom, Dan C.
    Lie, Elisabeth
    Ancuta, Ioan
    Victoria Hernandez, M.
    van Riel, Piet L. M. C.
    van Vollenhoven, Ronald
    Kvien, Tore K.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (07) : 1336 - 1342
  • [24] Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying antirheumatic drugs for rheumatoid arthritis
    Katchamart, Wanruchada
    Trudeau, Judith
    Phumethum, Veerapong
    Bombardier, Claire
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (04):
  • [25] Comparative Effectiveness of Tocilizumab in Combination with Methotrexate versus Tumor Necrosis Factor Inhibitors (TNFis) in Combination with Methotrexate in Patients with Rheumatoid Arthritis with Prior Exposure to TNFis
    Pappas, Dimitrios
    Blachley, Taylor
    Zlotnick, Steve
    Best, Jennie
    Emeanuru, Kelechi
    Kremer, Joel
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [26] COMPARATIVE EFFECTIVENESS OF TOCILIZUMAB IN COMBINATION WITH METHOTREXATE VERSUS TUMOR NECROSIS FACTOR INHIBITORS (TNFIS) IN COMBINATION WITH METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS WITH PRIOR EXPOSURE TO TNFIS
    Pappas, D. A.
    Blachley, T.
    Zlotnick, S.
    Best, J. H.
    Emeanuru, K.
    Kremer, J. M.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 989 - 989
  • [27] COMPARISON OF TOCILIZUMAB AS MONOTHERAPY OR IN COMBINATION WITH NON-BIOLOGICAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS) IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) AND AN INADEQUATE RESPONSE TO ANTI-TNF AGENTS
    Oestoer, A.
    Roman Ivorra, J. A.
    Wollenhaupt, J.
    Mpofu, C.
    Bernasconi, C.
    Sibilia, J.
    Bykerk, V.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 372 - 373
  • [28] PARTICULARITIES OF TREATMENT WITH CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDs) IN A GROUP OF PATIENTS WITH RHEUMATOID ARTHRITIS
    Schiotis, Ruxandra Elena
    Gosa, Dana
    Bocsan, Corina
    Suciu, Soimita
    Buzoianu, Anca Dana
    FARMACIA, 2017, 65 (03) : 479 - 484
  • [29] Effects of Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Response to Periodontal Treatment in Patients with Rheumatoid Arthritis
    Jung, Gyu-Un
    Han, Ji-Young
    Hwang, Kyung-Gyun
    Park, Chang-Joo
    Stathopoulou, Panagiota G.
    Fiorellini, Joseph P.
    BIOMED RESEARCH INTERNATIONAL, 2018, 2018
  • [30] FREQUENCY AND PREDICTORS OF SUSTAINED REMISSION IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS TREATED WITH CONVENTIONAL SYNTHETIC DISEASE MODIFYING DRUGS
    Zanframundo, G.
    Bugatti, S.
    Manzo, A.
    Benaglio, F.
    Sakellariou, G.
    Montecucco, C.
    Caporali, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 277 - 278
12345